Business Standard

Syngene International Ltd News

Upgrading acquired Stelis unit to triple Syngene's biologics capacity by H2

The company plans to expand research and manufacturing facilities, allocates Rs 500 cr capex for FY25

Upgrading acquired Stelis unit to triple Syngene's biologics capacity by H2
Updated On : 09 Jun 2024 | 3:04 PM IST

Berger Paints, Persistent: 5 oversold stocks that can bounce back up to 10%

HDFC Life, CoForge and Syngene are the other 3 stocks trading in oversold zone; Technically a RSI reading below 30 on the charts is considered oversold; here are the key levels.

Berger Paints, Persistent: 5 oversold stocks that can bounce back up to 10%
Updated On : 13 May 2024 | 8:56 AM IST

Syngene Q4 results: Net profit up 6% to Rs 189 cr, revenue declines 8%

Syngene International shares ended the day's trade on BSE at Rs 694.2 apiece, down one per cent

Syngene Q4 results: Net profit up 6% to Rs 189 cr, revenue declines 8%
Updated On : 25 Apr 2024 | 12:43 AM IST

Goldman Sachs bullish on Indian CDMO sector, recommends buying these stocks

Goldman Sachs attributes India's underpenetrated CDMO and CRO market to smaller capacities, lack of Innovation with little collaboration between Industry and academia

Goldman Sachs bullish on Indian CDMO sector, recommends buying these stocks
Updated On : 16 Apr 2024 | 12:35 PM IST

Syngene International Q3 results: Profit after tax up 4%; revenue rises 9%

About a week ago, Syngene International's share price declined by 3 per cent following UBS Global Research stock downgrade to sell

Syngene International Q3 results: Profit after tax up 4%; revenue rises 9%
Updated On : 25 Jan 2024 | 5:10 PM IST

Syngene International Q3 results: Net profit rises 1.64% to Rs 111.5 crore

Contract research and manufacturing services firm Syngene International Ltd on Thursday reported 1.64 per cent growth in consolidated net profit at Rs 111.5 crore in the third quarter ended December 2023, impacted by reduced funding in the US biotech segment and transaction costs of the acquisition of a multi-modal facility from Stelis Biopharma. The company had posted a profit of Rs 109.7 crore in the third quarter of last fiscal, Syngene International said in a regulatory filing. Consolidated revenue from operations during the quarter under review stood at Rs 853.5 crore as against Rs 785.9 crore in the year-ago period, it added. Total expenses in the third quarter were higher at Rs 740.9 crore as compared to Rs 663.2 crore in the same period a year ago, Syngene International said. The company incurred transaction costs of Rs 3.7 crore in the quarter ended December 2023 relating to the acquisition of multi-modal facility (Unit 3) from Stelis Biopharma Ltd (SBL) and the same has b

Syngene International Q3 results: Net profit rises 1.64% to Rs 111.5 crore
Updated On : 25 Jan 2024 | 4:46 PM IST